🔗 Share this article

As the United States proceeds with unprecedented changes to its vaccine schedules, one figure appears somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by questioning COVID-19 vaccinations in the global health crisis and has focused upon possible fatalities after COVID-19 immunization in her short position at the FDA.

Proposed Changes to Pediatric Immunization Program

Agency leaders were set to unveil radical revisions to the childhood immunization program earlier this month, bringing the US with Denmark’s vaccine program, it is understood – a substantial departure that would place the US out of alignment with many the global community with insufficient data for benefit. The planned update has been pushed back until the coming year.

In place of the top vaccines chief, Dr. Høeg is scheduled to speak at the gathering. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth appointee to head the center this calendar year.

A Shift at the Agency

The acting appointment might represent a closer partnership between the drug and biologics centers as Høeg and Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon dismantling already-approved vaccines at the FDA.

The new acting director has often pushed for halting specific pediatric shot schedules in the US so as to align more in line with Denmark, a country with comprehensive healthcare and a population roughly the population of Wisconsin’s.

In her initial comments, she has kept her attention on vaccines – usually the purview of Dr. Prasad, director of the FDA’s CBER – instead of medication approval.

Doubts Over Expertise

The appointee has little discernible track record in pharmaceutical research, approval processes or management, which has been customary for previous leaders of the biologics center. She has served at the FDA as a key advisor to the agency head and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for overseeing the CDER, remarked Jonathan Howard. “She has not conducted a clinical trial. She is not versed in managing a sizeable institution. She is not an expert in industry regulation.”

Past commissioners of CBER would “understand laws and regulations and the science of drug development”, commented Dr. Janet Woodcock. “Objectively, she has not acquired the kind of background that previous people who led CBER have had.”

The drug center has an vast portfolio at the agency, Woodcock pointed out.

“Many people just zeroes in on the novel medication approvals, but the generic drug division authorizes thousands of generic medications. There’s a biologic copycat branch, non-prescription drug unit and more, and each of these have to be supervised,” Dr. Woodcock said. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

There is also, a substantial leadership component to the role, which oversees over 5,000 personnel. “It’s a huge management job, if you do it right,” Woodcock concluded.

Official Statement and Disputed Policies

Regarding concerns about Høeg’s credentials and whether this assignment signifies more teamwork among FDA leaders on immunizations, a press secretary stated that the “concerns are based on inaccurate assumptions”.

“Her experience matches the functions of her job,” the spokesperson explained, pointing to the period Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg inherits the commissioner’s controversial priority voucher program, a disputed one-day therapy clearance system that apparently concerned her preceding directors. “By what process are these therapies being chosen for this voucher program? Who makes the calls?” Howard questioned. “There is a lot of secrecy occurring at the FDA right now.”

In general, he remarked, “the agency seems to be moving towards more relaxed oversight of pharmaceuticals, aside from vaccines.”

Public Track Record on Vaccines

Regarding vaccines, Høeg has a more established, if troubling, past, Howard have noted. She authored a analysis using unverified volunteer-provided data to estimate the frequency of heart inflammation following COVID-19 vaccination. She advised the Florida top health official Joseph Ladapo, who reportedly have altered data to imply Covid vaccines are pose a greater threat than they are.

Included in her “policy goals” for the incoming federal leadership featured altering regulations for novel immunizations and ending “non-essential” vaccines, she said after the election on a audio program. At the FDA, Dr. Høeg has according to sources floated the idea of preventing teenage boys from obtaining COVID-19 vaccinations.

“She is an complete ideologue who starts off with her preconceived notions and reverse-engineers to fit the science in a highly disingenuous, fraudulent manner,” Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg became part of other dissenters, {like|